Form 4: HCA Healthcare Executive Acquires Stock Appreciation Rights
SEC Form 4 Filing
Michael R. McAlevey, EVP Chief Legal & Admin Off at HCA Healthcare, reports acquisition of stock appreciation rights.
Summary
- On April 29, 2024, Michael R. McAlevey, EVP Chief Legal & Admin Off at HCA Healthcare, acquired 2,274 stock appreciation rights at a price of $311.42.
- These rights vest in four equal annual installments beginning on April 29, 2025.
- Following the transaction, McAlevey directly owns 2,274 derivative securities related to HCA Healthcare common stock.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing regarding executive compensation. It doesn't inherently convey positive or negative sentiment.
Industry Context
This filing is a routine disclosure of executive compensation in the healthcare industry, where stock-based compensation is common.
Comparison to Industry Standards
- Stock appreciation rights are a common form of executive compensation in publicly traded companies, including those in the healthcare sector.
- Companies like UnitedHealth Group (UNH) and CVS Health (CVS) also utilize stock-based compensation to align executive interests with shareholder value.
- The vesting schedule and terms of these rights are generally comparable to industry standards for executive compensation packages.
Key Dates
| Date | Description |
|---|---|
| 2022-01-25 | Date of Power of Attorney execution. |
| 2024-04-29 | Date of transaction: acquisition of stock appreciation rights. |
| 2025-04-29 | First vesting date for the stock appreciation rights. |
| 2034-04-29 | Expiration date for the stock appreciation rights. |
| 2024-05-01 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.